Chemistry:Clifutinib

From HandWiki

Clifutinib is an investigational new drug that is being developed by Sunshine Lake Pharma Co., Ltd. for the treatment of acute myeloid leukaemia (AML). It is a fms related receptor tyrosine kinase 3 (FLT3) inhibitor.[1][2]

References

  1. ↑ "Clifutinib besylate". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800049376. 
  2. ↑ "Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia". Journal of Medicinal Chemistry 68 (8): 7955–7972. April 2025. doi:10.1021/acs.jmedchem.4c03023. PMID 40213868. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Clifutinib&oldid=4582653"